4 results
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
With this study we compare the BHR and a conventional THP in a young and active patient group, to confirm that for this specific patient group and under favorable implantation circumstances, the BHR is a better solution regarding the post-op…
To validate the use of 3 and 7 Tesla nano-MRI in restaging locally advanced rectal cancer by node-to-node matching of the results of nano-MRI with pathology as the gold standard.
To validate nano-MRI on 7 Tesla with pathological findings.